01581nas a2200481   4500000000100000000000100001008004100002653003100043653004400074653005600118653001000174653004200184653001900226653003000245653004000275653001100315653004300326653006900369653008000438653002000518653003500538653003900573653000900612653001900621653001500640653003200655653001100687100001700698700001300715700001400728700001400742700001600756700001100772700001300783700002000796700002200816700002100838245017300859250001501032300001401047490000701061020003101068       2022                            d10aAdministration, Inhalation10aAdrenal Cortex Hormones/therapeutic use10aAdrenergic beta-2 Receptor Agonists/adverse effects10aAdult10aBronchodilator Agents/adverse effects10aCohort Studies10aDrug Therapy, Combination10aFormoterol Fumarate/adverse effects10aHumans10aMuscarinic Antagonists/adverse effects10a*Myocardial Infarction/chemically induced/diagnosis/epidemiology10a*Pulmonary Disease, Chronic Obstructive/diagnosis/drug therapy/epidemiology10aRisk Assessment10a*Stroke/diagnosis/epidemiology10aTiotropium Bromide/adverse effects10aLama10aUnited Kingdom10aaclidinium10aAcute myocardial infarction10aStroke1 aC. Rebordosa1 aE. Plana1 aA. Rubino1 aJ. Aguado1 aD. Martinez1 aA. Lei1 aS. Daoud1 aN. Saigi-Morgui1 aS. Perez-Gutthann1 aE. Rivero-Ferrer00aRisk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists  a2022/08/10  a1715-17330 v17  a1176-9106 (Print)1176-9106